Suppression of ARG kinase activity by STI571 induces cell cycle arrest through up-regulation of CDK inhibitor p18/INK4c

Abstract

ARG is a tyrosine kinase closely related to ABL, which is oncogenic when fused to the transcriptional repressor ETV6 (ETS translocation variant 6). In this study, we investigated the growth-inhibitory effect of STI571 (signal transduction inhibitor number 571) on ETV6/ARGexpressing cells and its molecular mechanisms using HT93A, a cell line derived from a patient with AML-M3 carrying t(1;12). STI571 effectively suppressed overall tyrosyl phosphorylation of intracellular proteins including ETV6/ARG fusion protein, as well as the growth of HT93A cells with an IC 50 of 200 nm. The growth inhibition was primarily because of cell cycle arrest at G1 phase when cells were treated with 100 nm STI571 for 48 h, and apoptosis was induced after longer exposure (72 h) or by a higher dose (1000 nm). STI571 increased the amount of p18/INK4c after 2 h of culture, when the cell cycle pattern was not yet affected, but not that of other CDK inhibitors (CKI). p18/INK4c was more abundant in G1-enriched fractions than in S-and G2/Menriched fractions of STI571-treated HT93A cells, suggesting that the upregulation of p18/INK4c expression correlates with the cell cycle arrest. Treatment of HT93A cells with antisense oligonucleotides against the Ink4c gene abrogated the growth inhibition by STI571. These results suggest that leukemogenesis by an aberrant ARG kinase involves the suppression of p18/INK4c, which is ubiquitously expressed and considered the major CKI in hematopoietic stem cells. STI571 can be an effective drug for the treatment of leukemias with deregulated ARG kinase activity.

Imatinib Mesylate (Gleevec) Inhibits Ovarian Cancer Cell Growth through a Mechanism Dependent on Platelet-Derived Growth Factor Receptor α and Akt Inactivation

“…In ovarian cancer cells, Imatinib has predominantly antiproliferative effects, arresting cells at G 0 /G 1 (Fig. 4), mechanism previously recorded for bcr-abl-positive hematopoietic cells and for PDGFR-expressing glioblastoma cells (46,54,55). Other reports have noted that Imatinib induces a significant increase in apoptosis in different tumor models.…”

Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines

“…A decrease in the proliferation of breast cancer cell lines was associated with a growth arrest at G2/M phase of the cell cycle, a signal that was probably mediated by c-kit (Roussidis et al, 2004). Two other reports described a different effect of IM on cell cycleaccumulation of cells mainly in G0/G1 phase -in haematological cell lines expressing BCR-ABL (Nishimura et al, 2003;Yin et al, 2004).…”

STI-571 (Imatinib Mesylate) Enhances the Apoptotic Efficacy of Pyrrolo-1,5-Benzoxazepine-6, a Novel Microtubule-Targeting Agent, in Both STI-571-Sensitive and -Resistant Bcr-Abl-Positive Human Chronic Myeloid Leukemia Cells

“…1 and 2). However, 65% of PBOX-6 treated K562 cells failed to (Nishimura et al, 2003). STI-571 alone (250 nM) was minimally toxic to cells and induced apoptosis in approximately 5% of the cells after 48 h. Interestingly, combined exposure of PBOX-6 with STI-571 significantly increased the percentage of apoptotic cells by inhibiting a prolonged G 2 M cell cycle arrest (P ϭ 0.001) and polyploidy (P ϭ 0.02) induced by PBOX-6 (Fig.…”